Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125106 | 0.86 | RAB9A (0.58) | KMT2AALDH1A1HPGDPOLBMAPT | |
| SCHEMBL4895351 | 0.80 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL19726938 | 0.79 | HPGD (0.73) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL5116644 | 0.77 | HPGD (0.71) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL21630176 | 0.77 | HPGD (0.71) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL29410065 | 0.77 | ALDH1A1 (0.74) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL5124500 | 0.77 | TDP1 (0.66) | KMT2AMEN1ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL11479230 | 0.76 | HPGD (0.69) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL2926521 | 0.76 | ALDH1A1 (0.69) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL5418744 | 0.75 | TDP1 (0.64) | KMT2AMEN1ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| WO-2007136640-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE | CELGENE CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | TNF, DHPS, IDO1 | KMT2A 2151/4885MEN1 3263/4885ALDH1A1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.